Mechanism of Tounong San in abscess-type lymph node tuberculosis treatment using network pharmacology

doi:10.19982/j.issn.1000-6621.20260041

Abstract

Abstract:

Objective: To explore the underlying molecular mechanism of Tounong San in abscess-type lymph node tuberculosis treatment using network pharmacology. Methods: The active components and potential target of Tounong San were searched and screened by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). These genes were mapped with the abscess-type lymph node tuberculosis related genes obtained by Genecards and OMIM database, thereby obtaining inter section targets. The String 11.5 database and Cytoscape 3.9.1 software were used to construct the protein-protein interaction (PPI) network and the active ingredient-core target network. Then, gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis of core target genes were carried out by using DAVlD 6.8 platform. Using the DAVID database, we performed intersection target gene ontology functional enrichment analysis and signaling pathway enrichment analysis of the Kyoto gene and genome database. Results: A total of 72 effective drug targets were screened out. Enrichment analysis indicated that the signaling pathways involved in Tounong San in abscess-type lymph node tuberculosis treatment were cell apoptosis and oxidative stress response signaling pathways. AKT1, TP53, ALB and CASP3 might be the key genes in Tounong San-mediated abscess-type lymph node tuberculosis treatment. Conclusion: Tounong San may influence AKT1, TP53, ALB and CASP3 gene expression, to achieve the purpose of treating abscess-type lymph node tuberculosis.

Key words: Tuberculosis, lymph node, Molecular mechanisms of pharmacological action, Tounong San, Network pharmacology

CLC Number:

R52
R285

Yang Bin, Cao Yuqing, Zong Xingyu, Wang Chaohong, Zhao Liping, Su Dahong, Gong Mengmeng, Ma Yan, Shi Yiheng, Lin Weibing, Zhao Jinfeng, Cheng Simin, Miao Tiantian, Wang Guirong. Mechanism of Tounong San in abscess-type lymph node tuberculosis treatment using network pharmacology[J]. Chinese Journal of Antituberculosis, 2026, 48(5): 677-686. doi: 10.19982/j.issn.1000-6621.20260041

Figures/Tables 9

药物	MOL编码	活性成分	口服生物利用度(%)	类药性
黄芪(Astragali Radix)	MOL000211	马瑞甙	55.38	0.78
	MOL000239	爪兰醇	50.83	0.29
	MOL000296	常春藤皂苷元	36.91	0.75
	MOL000033	3-羟基-10,13-二甲基-17-(5-异丙基辛烷-2-基)十六氢-1H-环戊烷[a]菲	36.23	0.78
	MOL000354	异鼠李素	49.60	0.31
	MOL000371	3,9-二-O-甲基尼索灵	53.74	0.48
	MOL000374	5'-羟基异穆罗拉马豆醇-2',5'-二-O-葡萄糖苷	41.72	0.69
	MOL000378	7-O-甲基异穆罗拉马豆醇	74.69	0.30
	MOL000379	9,10-二甲氧基紫檀烷-3-O-β-D-葡萄糖苷	36.74	0.92
	MOL000380	(6aR,11aR)-9,10-二甲氧基-6a,11a-二氢-6H-苯并呋喃并[3,2-c]色烯-3-醇	64.26	0.42
	MOL000387	联苯双酯	31.10	0.67
	MOL000392	芒柄花素	69.67	0.21
	MOL000398	异黄烷酮	109.99	0.30
	MOL000417	毛蕊异黄酮	47.75	0.24
	MOL000438	(3R)-3-(2-羟基-3,4-二甲氧基苯基)色满-7-醇	67.67	0.26
	MOL000439	异穆罗拉马豆醇-7,2'-二-O-葡萄糖苷	49.28	0.62
	MOL000442	1,7-二羟基-3,9-二甲氧基紫檀烯	39.05	0.48
皂角刺(Gleditsiae Spina)	MOL013179	非瑟酮	52.60	0.24
	MOL013296	黄颜木素	50.91	0.24
	MOL001736	(-)-花旗松素	60.51	0.27
	MOL006358	豆甾-4-烯-3,6-二酮	39.12	0.79
	MOL000073	表儿茶素	48.96	0.24
川芎(Chuanxiong Rhizoma)	MOL002135	杨梅酮	40.60	0.51
	MOL002140	川芎哚	65.95	0.27
	MOL002151	川芎萘呋内酯	47.66	0.24
	MOL002157	沃利内酯	42.31	0.71
金银花(Lonicerae Japonicae Flos)	MOL001495	亚麻酸乙酯	46.10	0.20
	MOL002707	六氢番茄红素	43.18	0.50
	MOL003006	金花环烯醚萜酸_qt (裂环马钱素类)	87.47	0.23
	MOL003014	断马钱子酸二丁缩醛_qt	53.65	0.29
	MOL002773	β-胡萝卜素	37.18	0.58
	MOL003036	金银花萜内酯	43.83	0.76
	MOL003044	金圣草黄素	35.85	0.27
	MOL003059	隐黄质	47.25	0.57
	MOL003062	4',5'-二脱氢-4,5'-逆-β,β-胡萝卜素-3,3'-二酮	31.22	0.55
	MOL003095	5-羟基-7-甲氧基-2-(3,4,5-三甲氧基苯基)色酮	51.96	0.41
	MOL003101	7-表-沃格苷	46.13	0.58
	MOL003108	金色酰胺醇酯 C	55.64	0.73
	MOL003111	金鸡纳苷_qt	55.79	0.50
	MOL003117	金银花缩醛 B_qt	61.19	0.19
	MOL003124	木樨苷	43.17	0.64
	MOL003128	二甲基断马钱子苷	48.46	0.48
	MOL000006	木犀草素	36.16	0.25
白芷(Angelicae Dahuricae Radix)	MOL001939	别欧前胡素	34.80	0.22
	MOL001941	异欧前胡素	34.55	0.22
	MOL001942	欧前胡素	45.46	0.23
	MOL001956	珊瑚菜素	32.69	0.28
	MOL002883	油酸乙酯	32.40	0.19
	MOL005789	新比克白芷内酯	36.18	0.31
	MOL005792	{5-[2'(R)-羟基-3'-甲基-3'-丁烯氧基]呋喃香豆素}	42.85	0.26
	MOL005800	比克白芷内酯	41.42	0.36
	MOL005802	丙二醇单油酸酯	37.60	0.26
	MOL005806	4-[(2S)-2,3-二羟基-3-甲基丁氧基]呋喃并[3,2-g]色烯-7-酮	39.99	0.29
	MOL005807	别比克白芷内酯	58.00	0.61
	MOL000953	胆固醇	37.87	0.68
	MOL001506	角鲨烯	33.55	0.42
	MOL001749	白芷香豆素	43.59	0.35
	MOL002644	珊瑚菜素	40.19	0.28
	MOL003588	欧前胡素苷元	36.31	0.22
	MOL003791	2-单油酸甘油酯	37.28	0.30
	MOL007514	11,14-二十碳二烯酸甲酯	39.67	0.23
	MOL013430	欧前胡素内酯	43.60	0.29
黄芪+皂角刺+金银花	MOL000422	山柰酚	41.88	0.24
	MOL000098	槲皮素	46.43	0.28
黄芪+川芎	MOL000433	阿魏酸	68.96	0.71
当归+皂角刺+金银花+白芷	MOL000358	β-谷甾醇	36.91	0.75
	MOL000449	豆甾醇	43.83	0.76
皂角刺+金银花	MOL002914	圣草酚	41.35	0.24
皂角刺+川芎	MOL000359	谷甾醇	36.91	0.75
川芎+金银花	MOL001494	亚麻酸甲酯	42.00	0.19

References 27

[1]	Chen ZK, Wu Z, Ye T, et al. Exploring the accuracy of the Xpert MTB/RIF assay in detecting lymph node tuberculosis: A systematic review and meta-analysis. PLoS One, 2025, 20(5):e0321507. doi:10.1371/journal.pone.0321507.
[2]	中国人民解放军总医院第八医学中心结核病医学部,《中国防痨杂志》编辑委员会,中国医疗保健国际交流促进会结核病防治分会. 浅表淋巴结结核的诊断与治疗专家共识. 中国防痨杂志, 2023, 45(6):531-542. doi:10.19982/j.issn.1000-6621.20230120.
[3]	Lin T, Yu Y, Luo J, et al. Clinical value of Metagenomic Next- and Third-Generation Sequencing applied in ultrasound-guided puncture biopsy for diagnosing lymph node tuberculosis. J Microbiol Immunol Infect, 2025, 58(3):340-346. doi:10.1016/j.jmii.2024.12.011.
[4]	Handa U, Mundi I, Mohan S. Nodal tuberculosis revisited: a review. J Infect Dev Ctries, 2012, 6(1): 6-12. doi:10.3855/jidc.2090.
[5]	傅良杰, 钮晓红. 内消瘰疬片辅助治疗初治肺结核并发颈部淋巴结结核患者的临床疗效. 中国防痨杂志, 2019, 41(10):1127-1131. doi:10.3969/j.issn.1000-6621.2019.10.012.
[6]	朱江春, 付义, 张乐, 等. 滇重楼散外敷联合抗结核药治疗浅表淋巴结结核的近期疗效. 昆明医科大学学报, 2018, 39(1):81-84. doi:10.3969/j.issn.1003-4706.2018.01.019.
[7]	孙燕芝, 邓永聪, 张瑛, 等. 中药抗痨Ⅰ号辅助治疗颈淋巴结核46例. 中国中西医结合杂志, 2003, 23(11):814. doi:10.3321/j.issn:1003-5370.2003.11.028.
[8]	钱佳燕, 黄子慧, 余洋, 等. 中西医综合治疗瘰疬病患者520例前瞻性队列研究. 中医杂志, 2020, 61(2):130-135. doi:10.13288/j.11-2166/r.2020.02.010.
[9]	贾威, 李丽, 蔡晓建, 等. 内消瘰疬丸加减联合常规西医治疗AIDS合并淋巴结核疗效观察. 海南医学, 2024, 35(17):2452-2458. doi:10.3969/j.issn.1003-6350.2024.17.005.
[10]	邓宇涛, 李智俐, 陈烨文, 等. 中医治疗淋巴结核研究述评. 中国保健营养, 2020, 30(7):40-41.
[11]	尚希钰, 张慧芳, 曹玉清, 等. 基于文献计量学的结核病中医药基础研究全球研究现状及热点分析. 中国防痨杂志, 2025, 47(4):482-497. doi:10.19982/j.issn.1000-6621.20240567.
[12]	中国中医科学院中医临床基础医学研究所, 浙江中医药大学附属丽水中医院, 中国防痨协会, 等. 结核分枝杆菌潜伏感染中医辨证分型及治法方药专家共识. 中国防痨杂志, 2026, 48(1): 1-8. doi:10.19982/j.issn.1000-6621.20250421.
[13]	丰银平, 张尊敬, 蔡秋杰, 等基于伏邪理论探讨结核分枝杆菌潜伏感染辨治思路. 中国防痨杂志, 2025, 47(10): 1249-1253. doi:10.19982/j.issn.1000-6621.20250327.
[14]	徐信义, 邱仕君. 《十药神书》临床用药特色. 河南中医, 2006, 26(6): 21-23. doi:10.3969/j.issn.1003-5028.2006.06.014.
[15]	曹振东, 李磊. 补中益气汤辅助治疗肺结核患者的效果及不良反应评价. 中国防痨杂志, 2024, 46(S1): 70-72. doi:10.3969/j.issn.1000-6621.2024.z1.018.
[16]	鹿振辉, 张惠勇, 张洪春, 等. 我国中医药防治结核病的现状与展望. 中国防痨杂志, 2020, 42(2): 88-90. doi:10.3969/j.issn.1000-6621.2020.02.002.
[17]	赵娅娅, 张宏. 阳和汤合透脓散治疗冷脓肿病案报道2例. 四川中医, 2024, 42(4):92-95. doi:10.3969/j.issn.1000-3649.2024.4.sczy202404025.
[18]	徐其锋, 安丽景, 王灿. 透脓散加减联合常规西药治疗肉芽肿性乳腺炎的效果. 中国药物滥用防治杂志, 2025, 31(2):318-320. doi:10.15900/j.cnki.zylf1995.2025.02.03.
[19]	赵丽萍, 孙晴, 王桂荣. 探讨中和汤治疗脓肿型淋巴结结核的作用机制. 世界临床药物, 2024, 45(6):590-596. doi:10.13683/j.wph.2024.06.004.
[20]	闫海峰, 张泽宇, 姚明鹤, 等. 桂枝-白芍治疗慢性心力衰竭作用机制的网络药理学分析. 中国中医基础医学杂志, 2023, 29(3):464-469.
[21]	刘春妘, 刘晓菲, 孙颖, 等. 基于网络药理学及分子对接探讨透脓散以IL-6为核心的免疫炎症调控干预肉芽肿性乳腺炎的机制及验证研究. 中医药信息, 2023, 40(1):43-51. doi:10.19656/j.cnki.1002-2406.20230107.
[22]	刘媛, 陈洁, 孙辉, 等. 中药治疗肺结核的用药规律及其核心药物作用机制的探讨. 中国防痨杂志, 2022, 44(2):131-140. doi:10.19982/j.issn.1000-6621.20210433.
[23]	Dai Y, Zhu C, Xiao W, et al. Mycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth. J Clin Invest, 2023, 133(8):e159941. doi:10.1172/JCI159941.
[24]	Yuan G, Bai Y, Zhang Y, et al. Data Mining Mycobacterium tuberculosis Pathogenic Gene Transcription Factors and Their Regulatory Network Nodes. Int J Genomics, 2018, 2018:3079730. doi:10.1155/2018/3079730.
[25]	Wang C, Wei LL, Shi LY, et al. Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis. Sci Rep, 2015, 5:15615. doi:10.1038/srep15615. pmid: 26499913
[26]	Kalita J, Shukla R, Pandey PC, et al. Balancing between apoptosis and survival biomarkers in the patients with tuberculous meningitis. Cytokine, 2022, 157:155960. doi:10.1016/j.cyto.2022.155960.
[27]	Zhan X, Yuan W, Ma R, et al. Mmu-let-7a-5p inhibits macrophage apoptosis by targeting CASP3 to increase bacterial load and facilities mycobacterium survival. PLoS One, 2024, 19(9):e0308095. doi:10.1371/journal.pone.0308095.

靶点	度值	介数中心性	接近中心性	靶点	度值	介数中心性	接近中心性
AKT1	55	343.47	0.82	ICAM1	33	27.37	0.65
TP53	53	284.51	0.80	MMP2	33	33.16	0.64
ALB	52	280.01	0.79	CASP9	32	32.39	0.63
CASP3	50	168.37	0.77	RELA	32	22.23	0.63
IL6	48	159.82	0.76	MAPK8	31	30.21	0.63
VEGFA	48	132.20	0.76	VCAM1	31	34.27	0.62
EGFR	48	172.77	0.76	CAV1	31	190.12	0.64
IL1B	45	101.71	0.73	NFE2L2	31	91.20	0.62
PPARG	45	200.69	0.73	MCL1	30	47.61	0.63
CTNNB1	43	151.16	0.72	MAPK14	30	44.68	0.62
EGF	40	67.77	0.69	STAT1	29	20.73	0.62
NFKBIA	38	45.15	0.68	PARP1	25	35.78	0.59
CASP8	37	68.56	0.66	PRKCA	24	33.05	0.59
HMOX1	37	99.35	0.66	NR3C1	24	143.51	0.60
CREB1	34	168.85	0.65	AHR	24	41.95	0.60
ERBB2	34	202.75	0.65	MPO	23	16.79	0.58

序号	靶点	基因名称	度值
1	Calmodulin-1	CALM1	14
2	Caspase-3	CASP3	13
3	Apoptosis regulator Bcl-2	BCL2	11
4	Apoptosis regulator BAX	BAX	10
5	Caspase-9	CASP9	10
6	Transcription factor p65	RELA	9
7	Peroxisome proliferator-activated receptor gamma	PPARG	9
8	AKT Serine/Threonine Kinase 1	AKT1	9
9	Caspase-8	CASP8	9
10	Heme oxygenase 1	HMOX1	8